ClinicalTrials.Veeva

Menu

Enzastaurin for Patients With Metastatic Colorectal Cancer

Lilly logo

Lilly

Status and phase

Completed
Phase 2

Conditions

Colonic Neoplasms

Treatments

Drug: Enzastaurin HCl

Study type

Interventional

Funder types

Industry

Identifiers

NCT00192114
9098
H6Q-MC-JCAR (Other Identifier)

Details and patient eligibility

About

Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer

Enrollment

28 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosed with colorectal cancer that is advanced or metastatic (has spread to other parts of the body); able to visit the doctor's office every 28 days for at least 6 months; able to swallow tablets

Exclusion criteria

  • women cannot be pregnant or breastfeeding; no history of significant heart disease or any other significant medical problems as determined by the participant's physician

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

28 participants in 1 patient group

Enzastaurin HCl
Experimental group
Treatment:
Drug: Enzastaurin HCl

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems